Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Metadata
Title
Fragile X: Leading the way for targeted treatments in autism
Authors
Lulu W. Wang
Elizabeth Berry-Kravis
Randi J. Hagerman
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Neurotherapeutics / Issue 3/2010
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1016/j.nurt.2010.05.005

Other articles of this Issue 3/2010

Neurotherapeutics 3/2010 Go to the issue

Review Article

Complementary and alternative medicine in autism: An evidence-based approach to negotiating safe and efficacious interventions with families

Review Article

Autism and oxytocin: New developments in translational approaches to therapeutics

Review Article

Immune dysfunction in autism: A pathway to treatment

Abstract

Abstracts from the ASENT 2010 annual meeting March 4–6, 2010

Review Article

Tetrahydrobiopterin as a novel therapeutic intervention for autism

Review Article

Improving the prediction of response to therapy in autism